{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:11:45Z","timestamp":1791529905435,"version":"4.3.4"},"reference-count":100,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without macrophage activation syndrome. Recommendations regarding tapering and discontinuing treatment in inactive systemic JIA are also provided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed clinically relevant Patient\/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients\/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Similar to those published in 2019, these JIA recommendations are based on clinical phenotypes of JIA, rather than a specific classification schema. This guideline provides recommendations for initial and subsequent treatment of JIA with oligoarthritis, TMJ arthritis, and systemic JIA as well as for tapering and discontinuing treatment in subjects with inactive systemic JIA. Other aspects of disease management, including factors that influence treatment choice and medication tapering, are discussed. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis. It serves as a tool to support clinicians, patients, and caregivers in decision\u2010making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision\u2010making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient\/caregiver.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.24853","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:01:53Z","timestamp":1646179313000},"page":"521-537","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.1002","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-5361","authenticated-orcid":false,"given":"Karen B.","family":"Onel","sequence":"first","affiliation":[{"name":"Hospital for Special Surgery  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-1339","authenticated-orcid":false,"given":"Daniel B.","family":"Horton","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School  New Brunswick New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0130","authenticated-orcid":false,"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center and University of Cincinnati  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-594X","authenticated-orcid":false,"given":"Susan","family":"Shenoi","sequence":"additional","affiliation":[{"name":"Seattle Children's Hospital and Research Center and University of Washington  Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Cuello","sequence":"additional","affiliation":[{"name":"McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9552-6464","authenticated-orcid":false,"given":"Sheila T.","family":"Angeles\u2010Han","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center and University of Cincinnati  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L.","family":"Becker","sequence":"additional","affiliation":[{"name":"Duke University  Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2661-3086","authenticated-orcid":false,"given":"Randy Q.","family":"Cron","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Feldman","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polly J.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"University of Iowa Carver College of Medicine  Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Gewanter","sequence":"additional","affiliation":[{"name":"Children's Hospital of Richmond at VCU  Richmond Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-2581","authenticated-orcid":false,"given":"Jaime","family":"Guzman","sequence":"additional","affiliation":[{"name":"BC Children's Hospital  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-3390","authenticated-orcid":false,"given":"Yukiko","family":"Kimura","sequence":"additional","affiliation":[{"name":"Hackensack Meridian School of Medicine  Hackensack New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzielan","family":"Lee","sequence":"additional","affiliation":[{"name":"Stanford University  Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Murphy","sequence":"additional","affiliation":[{"name":"Louisiana Department of Health  New Orleans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Nigrovic","sequence":"additional","affiliation":[{"name":"Boston Children's Hospital and Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3322-4089","authenticated-orcid":false,"given":"Michael J.","family":"Ombrello","sequence":"additional","affiliation":[{"name":"NIH  Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Egla","family":"Rabinovich","sequence":"additional","affiliation":[{"name":"Duke University  Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-1375","authenticated-orcid":false,"given":"Melissa","family":"Tesher","sequence":"additional","affiliation":[{"name":"University of Chicago  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinka","family":"Twilt","sequence":"additional","affiliation":[{"name":"University of Calgary and Alberta Children's Hospital  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Klein\u2010Gitelman","sequence":"additional","affiliation":[{"name":"Ann &amp; Robert Lurie Children's Hospital of Chicago and Northwestern University  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8508-3578","authenticated-orcid":false,"given":"Fatima","family":"Barbar\u2010Smiley","sequence":"additional","affiliation":[{"name":"Nationwide Children's Hospital  Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8855-845X","authenticated-orcid":false,"given":"Ashley M.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Children's Mercy Hospital  Kansas City Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Edelheit","sequence":"additional","affiliation":[{"name":"Connecticut Children's Medical Center  Hartford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriah","family":"Gillispie\u2010Taylor","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine  Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Hays","sequence":"additional","affiliation":[{"name":"Penn State Health Children's Hospital  Hershey Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-970X","authenticated-orcid":false,"given":"Melissa L.","family":"Mannion","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-2343","authenticated-orcid":false,"given":"Rosemary","family":"Peterson","sequence":"additional","affiliation":[{"name":"Dell Children's Medical Center  Austin Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Emory University  Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Saad","sequence":"additional","affiliation":[{"name":"University of Michigan  Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Sullivan","sequence":"additional","affiliation":[{"name":"ECRI Institute Plymouth Meeting  Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Szymanski","sequence":"additional","affiliation":[{"name":"Johns Hopkins All Children's Hospital  St. Petersburg Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-9443","authenticated-orcid":false,"given":"Rebecca","family":"Trachtman","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Turgunbaev","sequence":"additional","affiliation":[{"name":"American College of Rheumatology  Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keila","family":"Veiga","sequence":"additional","affiliation":[{"name":"Maria Fareri Children's Hospital  Valhalla New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7695-2022","authenticated-orcid":false,"given":"Amy S.","family":"Turner","sequence":"additional","affiliation":[{"name":"American College of Rheumatology  Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Reston","sequence":"additional","affiliation":[{"name":"ECRI Institute Plymouth Meeting  Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman T","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","article-title":"2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications","volume":"65","author":"Ringold S","year":"2013","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non\u2010systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold S","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.40885","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis\u2013associated uveitis","volume":"71","author":"Angeles\u2010Han ST","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_6_1","unstructured":"OnelKB ShenoiS.2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis (JIA): therapeutic approaches for oligoarthritis temporomandibular joint arthritis (TMJ) and systemic JIA medication monitoring immunizations and non\u2010pharmacologic therapies. Presented at ACR Convergence;2020November 3\u201310; Atlanta Georgia."},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines. 15. Going from evidence to recommendation\u2014determinants of a recommendation's direction and strength","volume":"66","author":"Andrews JC","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","journal-title":"BMJ"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers MC","year":"2010","journal-title":"CMAJ"},{"key":"e_1_2_8_10_1","article-title":"American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging","author":"Onel KB","year":"2021","journal-title":"Arthritis Rheumatol 2022"},{"key":"e_1_2_8_11_1","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997","volume":"25","author":"Petty RE","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/acr.23922","article-title":"Real\u2010world effectiveness of common treatment strategies for juvenile idiopathic arthritis: results from a Canadian cohort","volume":"72","author":"Chhabra A","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s10067-005-1116-7","article-title":"Low\u2010dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra\u2010articular corticosteroids","volume":"24","author":"Brik R","year":"2005","journal-title":"Clin Rheumatol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/03009748409111307","article-title":"Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis: assessment of tolerance and efficacy in a single\u2010centre 24\u2010week double\u2010blind parallel study","volume":"13","author":"Kvien TK","year":"1984","journal-title":"Scand J Rheumatol"},{"key":"e_1_2_8_15_1","first-page":"291","article-title":"Probability of remission of juvenile idiopathic arthritis following treatment with steroid joint injection","volume":"32","author":"Sato JD","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00431-007-0525-9","article-title":"Factors influencing the efficacy of intra\u2010articular steroid injections in patients with juvenile idiopathic arthritis","volume":"167","author":"Marti P","year":"2008","journal-title":"Eur J Pediatr"},{"key":"e_1_2_8_17_1","first-page":"2696","article-title":"A subgroup\u2010specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis","volume":"27","author":"Breit W","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/rheumatology\/keg358","article-title":"Comparison of intra\u2010articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis","volume":"42","author":"Zulian F","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/rheumatology\/keh313","article-title":"Triamcinolone acetonide and hexacetonide intra\u2010articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double\u2010blind trial","volume":"43","author":"Zulian F","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_20_1","first-page":"2507","article-title":"Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis","volume":"31","author":"Eberhard BA","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12969-017-0196-7","article-title":"Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh\u2010Out cohort","volume":"15","author":"Guzman J","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_22_1","first-page":"e64681","article-title":"Adrenal insufficiency in children with juvenile idiopathic arthritis (JIA) treated with prednisolone","volume":"10","author":"Sadeghi PA","year":"2019","journal-title":"J Compr Ped"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","article-title":"Intra\u2010articular corticosteroids versus intra\u2010articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open\u2010label trial","volume":"389","author":"Ravelli A","year":"2017","journal-title":"Lancet"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1546-0096-12-35","article-title":"Predictors of response to methotrexate in juvenile idiopathic arthritis","volume":"12","author":"Albarouni M","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-019-0355-0","article-title":"A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease\u2010modifying antirheumatic therapy in juvenile idiopathic arthritis","volume":"17","author":"Bava C","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12969-016-0099-z","article-title":"Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration","volume":"14","author":"Franova J","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_27_1","first-page":"360","article-title":"Sulfasalazine therapy for juvenile rheumatoid arthritis","volume":"23","author":"Imundo LF","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3899\/jrheum.090874","article-title":"Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice","volume":"37","author":"Foeldvari I","year":"2010","journal-title":"J Rheumatol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.21037","article-title":"Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritis [letter]","volume":"52","author":"Haapasaari J","year":"2005","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/14397595.2018.1516329","article-title":"Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4\u2009years and children of older age groups using the propensity score matching method","volume":"29","author":"Alexeeva E","year":"2019","journal-title":"Mod Rheumatol"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kes373","article-title":"Tumour necrosis factor\u2010blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register","volume":"52","author":"Anink J","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE\u2010JIA): a multicentre randomised open\u2010label clinical trial","volume":"70","author":"Tynjala P","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell DJ","year":"2000","journal-title":"N Engl J Med"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3899\/jrheum.200437","article-title":"Biologic switching among non\u2010systemic juvenile idiopathic arthritis patients: a cohort study in the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"48","author":"Mannion ML","year":"2020","journal-title":"J Rheumatol"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-020-02326-5","article-title":"Long\u2010term safety and effectiveness of etanercept in JIA: an 18\u2010year experience from the BiKeR registry","volume":"22","author":"Armaroli G","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff G","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/acr.23709","article-title":"Time of disease\u2010modifying antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug\u2010free remission in young adulthood","volume":"71","author":"Minden K","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/kev434","article-title":"Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"55","author":"Kearsley\u2010Fleet L","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular\u2010course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite N","year":"2009","journal-title":"Clin Rheumatol"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-018-1571-6","article-title":"Predicting unfavorable long\u2010term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study","volume":"20","author":"Rypdal V","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13075-019-2060-2","article-title":"Validation of prediction models of severe disease course and non\u2010achievement of remission in juvenile idiopathic arthritis: part 1\u2014results of the Canadian model in the Nordic cohort","volume":"21","author":"Rypdal V","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_8_42_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/acr.24192","article-title":"Outcome measures for juvenile idiopathic arthritis disease activity","volume":"72","author":"Trincianti C","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/art.21389","article-title":"Patterns of clinical remission in select categories of juvenile idiopathic arthritis","volume":"52","author":"Wallace CA","year":"2005","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace CA","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro A","year":"2009","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_46_1","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2012-202031","article-title":"Validity of a three\u2010variable Juvenile Arthritis Disease Activity Score in children with new\u2010onset juvenile idiopathic arthritis","volume":"72","author":"McErlane F","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_47_1","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/rheumatology\/keaa240","article-title":"Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis","volume":"59","author":"Tibaldi J","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_48_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli A","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","article-title":"Treat\u2010to\u2010target study for improved outcome in polyarticular juvenile idiopathic arthritis","volume":"79","author":"Klein A","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_50_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3899\/jrheum.190268","article-title":"Outcome monitoring and clinical decision support in polyarticular juvenile idiopathic arthritis","volume":"47","author":"Buckley L","year":"2020","journal-title":"J Rheumatol"},{"key":"e_1_2_8_51_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12969-018-0259-4","article-title":"Orofacial symptoms and oral health\u2010related quality of life in juvenile idiopathic arthritis: a two\u2010year prospective observational study","volume":"16","author":"Rahimi H","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_52_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/acr.23003","article-title":"Temporomandibular joint involvement in association with quality of life, disability, and high disease activity in juvenile idiopathic arthritis","volume":"69","author":"Frid P","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_8_53_1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3899\/jrheum.190168","article-title":"Magnetic resonance imaging followup of temporomandibular joint inflammation, deformation, and mandibular growth in juvenile idiopathic arthritis patients receiving systemic treatment","volume":"47","author":"Bollhalder A","year":"2020","journal-title":"J Rheumatol"},{"key":"e_1_2_8_54_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3899\/jrheum.171306","article-title":"Risk factors for intraarticular heterotopic bone formation in the temporomandibular joint in juvenile idiopathic arthritis","volume":"45","author":"Stoll ML","year":"2018","journal-title":"J Rheumatol"},{"key":"e_1_2_8_55_1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3899\/jrheum.101198","article-title":"Heterotopic ossification of the temporomandibular joint in juvenile idiopathic arthritis","volume":"38","author":"Ringold S","year":"2011","journal-title":"J Rheumatol"},{"key":"e_1_2_8_56_1","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3899\/jrheum.141502","article-title":"Magnetic resonance imaging assessment of temporomandibular joint involvement and mandibular growth following corticosteroid injection in juvenile idiopathic arthritis","volume":"42","author":"Lochbuhler N","year":"2015","journal-title":"J Rheumatol"},{"key":"e_1_2_8_57_1","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.joms.2016.06.189","article-title":"Quantifying the effect of temporomandibular joint intra\u2010articular steroid injection on synovial enhancement in juvenile idiopathic arthritis","volume":"74","author":"Resnick CM","year":"2016","journal-title":"J Oral Maxillofac Surg"},{"key":"e_1_2_8_58_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1067\/mod.2000.104953","article-title":"Effect of methotrexate on the temporomandibular joint and facial morphology in juvenile rheumatoid arthritis patients","volume":"118","author":"Ince DO","year":"2000","journal-title":"Am J Orthod Dentofacial Orthop"},{"key":"e_1_2_8_59_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3899\/jrheum.191169","article-title":"Systemic treatment for temporomandibular joint arthritis in juvenile idiopathic arthritis","volume":"47","author":"Stoustrup P","year":"2020","journal-title":"J Rheumatol"},{"key":"e_1_2_8_60_1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/annrheumdis-2016-210324","article-title":"Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications","volume":"76","author":"Ombrello MJ","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_61_1","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti F","year":"2012","journal-title":"N Engl J Med"},{"key":"e_1_2_8_62_1","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto N","year":"2012","journal-title":"N Engl J Med"},{"key":"e_1_2_8_63_1","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin\u20101 (IL\u20101) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL\u20101 blockade","volume":"201","author":"Pascual V","year":"2005","journal-title":"J Exp Med"},{"key":"e_1_2_8_64_1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaborative initiative","volume":"68","author":"Ravelli A","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_65_1","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia F","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_66_1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new\u2010onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt EM","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_8_67_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-017-0157-1","article-title":"Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans","volume":"15","author":"Kimura Y","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_68_1","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first\u2010line treatment with recombinant interleukin\u20101 receptor antagonist in steroid\u2010naive patients with new\u2010onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert SJ","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_69_1","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis\u2013associated lung disease: characterization and risk factors","volume":"71","author":"Schulert GS","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_70_1","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper VE","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_71_1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.2106\/00004623-197658080-00010","article-title":"Joint replacement surgery in patients under thirty","volume":"58","author":"Bsila RS","year":"1976","journal-title":"J Bone Joint Surg Am"},{"key":"e_1_2_8_72_1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.38384","article-title":"US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis","volume":"66","author":"Mertelsmann\u2010Voss C","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_73_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12969-017-0219-4","article-title":"Patient characteristics associated with response to NSAID monotherapy in children with systemic juvenile idiopathic arthritis","volume":"16","author":"Sura A","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_74_1","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomized, placebo\u2010controlled, crossover trial of low\u2010dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo P","year":"2000","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_75_1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin\u20101 receptor antagonist as first\u2010line monotherapy in new\u2010onset systemic juvenile idiopathic arthritis: results from a five\u2010year follow\u2010up study","volume":"71","author":"Ter Haar NM","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_76_1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jpeds.2004.08.020","article-title":"Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study","volume":"145","author":"Lehman TJ","year":"2004","journal-title":"J Pediatr"},{"key":"e_1_2_8_77_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","article-title":"A phase II, multicenter, open\u2010label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features","volume":"64","author":"Ruperto N","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_78_1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long\u2010term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell DJ","year":"2013","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_79_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double\u2010blind, placebo\u2010controlled trial with the interleukin\u20101 receptor antagonist anakinra in patients with systemic\u2010onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier P","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_80_1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2011-201060","article-title":"Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register","volume":"72","author":"Otten MH","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_81_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/rheumatology\/33.5.495","article-title":"Epstein\u2010Barr virus\u2010associated haemophagocytic syndrome in a patient with juvenile chronic arthritis","volume":"33","author":"Davies SV","year":"1994","journal-title":"Br J Rheumatol"},{"key":"e_1_2_8_82_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jmv.1890390216","article-title":"Hepatitis A causing a second episode of virus\u2010associated haemophagocytic lymphohistiocytosis in a patient with Still's disease","volume":"39","author":"McPeake JR","year":"1993","journal-title":"J Med Virol"},{"key":"e_1_2_8_83_1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00296-016-3545-9","article-title":"Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus","volume":"36","author":"Aytac S","year":"2016","journal-title":"Rheumatol Int"},{"key":"e_1_2_8_84_1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily EM","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_85_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/24725625.2020.1741073","article-title":"Successful use of short\u2010term add\u2010on tocilizumab for refractory adult\u2010onset still's disease with macrophage activation syndrome despite treatment with high\u2010dose glucocorticoids, cyclosporine, and etoposide","volume":"4","author":"Ohmura SI","year":"2020","journal-title":"Mod Rheumatol Case Rep"},{"key":"e_1_2_8_86_1","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","volume":"37","author":"Sonmez HE","year":"2018","journal-title":"Clin Rheumatol"},{"key":"e_1_2_8_87_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12969-019-0342-5","article-title":"Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey","volume":"17","author":"Shenoi S","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_88_1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/art.41488","article-title":"Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from an open\u2010label, randomized phase IIIb\/IV study","volume":"73","author":"Quartier P","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_89_1","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long\u2010term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice JB","year":"2017","journal-title":"Clin Ther"},{"key":"e_1_2_8_90_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/rheumatology\/39.2.198","article-title":"Juvenile chronic arthritis into adulthood: a long\u2010term follow\u2010up study","volume":"39","author":"Zak M","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_91_1","first-page":"1989","article-title":"Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort","volume":"29","author":"Oen K","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_92_1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic\u2010onset juvenile idiopathic arthritis: a randomised, double\u2010blind, placebo\u2010controlled, withdrawal phase III trial","volume":"371","author":"Yokota S","year":"2008","journal-title":"Lancet"},{"key":"e_1_2_8_93_1","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/art.10544","article-title":"The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis","volume":"46","author":"Al\u2010Matar MJ","year":"2002","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_94_1","unstructured":"USFoodandDrugAdministration.Current and resolved drug shortages and discontinuations reported to FDA: triamcinolone hexacetonide. URL:https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/dsp_ActiveIngredientDetails.cfm?AI=Triamcinolone%20Hexacetonide%20Injectable%20Suspension%20(Aristospan)&st=c."},{"key":"e_1_2_8_95_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jadohealth.2013.02.004","article-title":"I'm the one taking it\u201d: adolescent participation in chronic disease treatment decisions","volume":"53","author":"Lipstein EA","year":"2013","journal-title":"J Adolesc Health"},{"key":"e_1_2_8_96_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12969-016-0113-5","article-title":"Parents' information needs and influential factors when making decisions about TNF\u2010\u03b1 inhibitors","volume":"14","author":"Lipstein EA","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_97_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.10863","article-title":"Outcome in adults with juvenile idiopathic arthritis: a quality of life study","volume":"48","author":"Foster HE","year":"2003","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_98_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12969-016-0073-9","article-title":"A recurring rollercoaster ride: a qualitative study of the emotional experiences of parents of children with juvenile idiopathic arthritis","volume":"14","author":"Gomez\u2010Ramirez O","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"e_1_2_8_99_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/art.41390","article-title":"New medications are needed for children with juvenile idiopathic arthritis","volume":"72","author":"Brunner HI","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_100_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/acr.23853","article-title":"Long\u2010term outcomes in juvenile idiopathic arthritis: eighteen years of follow\u2010up in the population\u2010based Nordic Juvenile Idiopathic Arthritis Cohort","volume":"72","author":"Glerup M","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_2_8_101_1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","article-title":"The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh\u2010Out cohort","volume":"75","author":"Guzman J","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.24853","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:47:18Z","timestamp":1759416438000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.24853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/acr.24853"],"URL":"https:\/\/doi.org\/10.1002\/acr.24853","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"2021-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}